Q&A: Janssen on where it is heading with real world evidence
Getting to grips with real world evidence can help companies get their medicines to patients, but there are multiple challenges too, such as “messy” data and building trust, says Nigel Hughes of Janssen Pharmaceutical.
You may also be interested in...
Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.
Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.